Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

BACKGROUND The Registry to EValuate Early And Long-term pulmonary arterial hypertension disease management (REVEAL Registry) was established to provide updated characteristics of patients with pulmonary arterial hypertension (PAH) and to improve diagnosis, treatment, and management. METHODS Fifty-four US centers enrolled consecutively screened patients with World Health Organization group I PAH who met expanded hemodynamic criteria of mean pulmonary arterial pressure (PAP) > 25 mm Hg at rest (30 mm Hg with exercise), pulmonary capillary wedge pressure (PCWP) <or= 18 mm Hg, and pulmonary vascular resistance >or= 240 dynes x s x cm(-5). Patients meeting the traditional hemodynamic definition (PCWP <or= 15 mm Hg) were compared with those with a PCWP of 16 to 18 mm Hg. RESULTS Between March 2006 and September 2007, 2,967 patients enrolled. Among 2,525 adults meeting traditional hemodynamic criteria, the mean age was 53 +/- 14 years, and 2,007 (79.5%) were women. The mean duration between symptom onset and diagnostic catheterization was 2.8 years, and 1,008 (41.3%) patients were treated with more than one pulmonary vascular-targeted medication. Compared with patients meeting the traditional hemodynamic definition of PAH, patients with a PCWP of 16 to 18 mm Hg were older, more obese, had a lower 6-min walk distance, and had a higher incidence of systemic hypertension, sleep apnea, renal insufficiency, and diabetes. CONCLUSIONS Patients in the REVEAL Registry are older and more often female than in previous descriptions. Delays between symptom onset and diagnostic catheterization persist. Many treatment regimens are fundamentally empirical, and data will be required to determine outcomes, improve risk stratification, and develop and validate more precise prognostic tools. Patients with PCWP of 16 to 18 mm Hg differ in a number of important respects from those meeting the traditional hemodynamic definition of PAH.

[1]  W. Cornwell,et al.  Pulmonary arterial hypertension. , 2011, Current problems in cardiology.

[2]  G. Raskob,et al.  397: REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated with Congenital Heart Disease , 2009 .

[3]  G. Raskob,et al.  708: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Pulmonary Vascular Disease Associated with Congenital Heart Disease , 2009 .

[4]  G. Raskob,et al.  228: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension , 2009 .

[5]  M. Cheitlin Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial , 2009 .

[6]  G. Raskob,et al.  A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH) , 2008 .

[7]  G. Raskob,et al.  Design of the REVEAL registry for US patients with pulmonary arterial hypertension. , 2008, Mayo Clinic proceedings.

[8]  K. Lewis Pulmonary Arterial Hypertension in France: Results from a National Registry , 2007 .

[9]  D. Badesch,et al.  Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. , 2007, Chest.

[10]  R. Barst,et al.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[11]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[12]  L. Abenhaim,et al.  Temporal trends and drug exposures in pulmonary hypertension: an American experience. , 2006, American heart journal.

[13]  R. Barst,et al.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.

[14]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[15]  D. Badesch,et al.  Evaluation and Management of the Patient with Pulmonary Arterial Hypertension , 2005, Annals of Internal Medicine.

[16]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[17]  A. Torbicki,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension , 2004 .

[18]  Horst Olschewski,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.

[19]  L. Rubin Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[20]  D. Mccrory,et al.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[21]  D. Mccrory,et al.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[22]  R. Dixon,et al.  Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[23]  W. Seeger,et al.  Clinical classification of pulmonary hypertension. , 2001, Clinics in chest medicine.

[24]  D. Mccrory,et al.  Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[25]  P. Kao,et al.  High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. , 2002, Chest.

[26]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[27]  Orris,et al.  INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .

[28]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[29]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[30]  A. Kashyap,et al.  Thyroid disease and primary pulmonary hypertension. , 2001, JAMA.

[31]  G. Simonneau,et al.  EFFECTS OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULM HT: A RANDOMIZED PLACEBO CONTROLLED STUDY , 2001 .

[32]  C. Campo López,et al.  [Hyperthyroidism and pulmonary hypertension]. , 2001, Revista clinica espanola.

[33]  A. Arroliga,et al.  Primary pulmonary hypertension and thyroid disease. , 2000, Chest.

[34]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[35]  S. Schneeweiss,et al.  Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. , 2000, Chest.

[36]  A. Arroliga,et al.  High prevalence of hypothyroidism in patients with primary pulmonary hypertension. , 1999, The American journal of the medical sciences.

[37]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[38]  J. Madans,et al.  Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. , 1997, American journal of epidemiology.

[39]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[40]  D. Wysowski,et al.  Use of Menopausal Estrogens and Medroxyprogesterone in the United States, 1982–1992 , 1995, Obstetrics and gynecology.

[41]  B. Groves,et al.  Hypothyroidism and Primary Pulmonary Hypertension: An Autoimmune Pathogenetic Link? , 1993, Annals of Internal Medicine.

[42]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[43]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.